Skip to main content
Silo Pharma, Inc. logo

Silo Pharma, Inc. — Investor Relations & Filings

Ticker · SILO ISIN · US82711P2011 US Manufacturing
Filings indexed 351 across all filing types
Latest filing 2023-11-14 Regulatory Filings
Country US United States of America
Listing US SILO

About Silo Pharma, Inc.

https://silopharma.com/

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved medical conditions by merging traditional pharmaceuticals with psychedelic research. The company's portfolio targets a range of indications, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Key development programs include SPC-15 for post-traumatic stress disorder (PTSD) and SP-26 for fibromyalgia, alongside preclinical assets for Alzheimer's disease and multiple sclerosis. Silo Pharma utilizes the 505(b)(2) regulatory pathway for certain licensed therapeutics to potentially streamline the approval process. The company conducts its research through collaborations with universities and laboratories to build its intellectual property portfolio.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings
2023-11-14 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2023
2023-11-13 English
DEFINITIVE ADDITIONAL MATERIALS
Regulatory Filings
2023-10-23 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2023-10-23 English
PRELIMINARY PROXY STATEMENT
Regulatory Filings
2023-10-10 English
CURRENT REPORT
Regulatory Filings
2023-08-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.